

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Mota Ventures Corp. (the “Issuer”).

Trading Symbol: **MOTA**

Number of Outstanding Listed Securities: **107,117,118**

Date: **April 7, 2020**

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer’s ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are “material information” as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term “Issuer” includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

- 1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

On March 2, 2020, the Issuer terminated its letter of intent with Stillcanna Inc. dated February 25, 2020 (the “Letter of Intent”). The decision to end merger discussions between the companies was the result of the market conditions at the time, which made it difficult to meet the requirements of the Letter of Intent, as well as negative investor sentiment.

On March 4, 2020, the Issuer engaged AGORA Internet Relations to deliver online advertising and marketing services for an initial twelve-month term. The fee for the services is C\$60,000 and will be paid in five equal instalments over the term in common shares of the Issuer. The Company also entered into a 12-month programmatic digital advertising campaign with Native Ads, Inc. in March for a total cost of C\$80,000

On March 14, 2020, the Issuer’s online brand, First Class CBD, launched a new “Immune Support” product line in the United States, which has seen significant growth and customer interest.

On March 26, 2020, the Issuer completed its acquisition of the Spanish trademark “Sativida” from Sativida OU (Estonia). The Issuer will license the trademark back to Sativida OU’s subsidiary, VIDA BCN LABS S.L. (collectively with Sativida OU, “Sativida”) in exchange for a royalty associated with the gross revenues generated by Sativida. The Issuer also acquired the right to acquire all of the outstanding share capital of Sativida at any time for €1.00. Sativida is a producer and online retailer of cannabidiol (“CBD”) and branded CBD products in various jurisdictions in Europe, including Spain, Portugal, Austria, Germany, France and the United Kingdom.

2. Provide a general overview and discussion of the activities of management.

Management of the Issuer has been engaged in growing its online CBD businesses in the United States (First Class CBD) and Europe (Sativida), moving its Colombian operations forward, organizing a non-brokered private placement financing and conducting due diligence on a potential strategic acquisition in the Canadian CBD sector.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

The Issuer, through First Class CBD, launched a new “Immune Support” product line in the United States on March 14, 2020.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned. **None.**

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

On March 26, 2020, the Issuer completed its acquisition of the Spanish trademark "Sativida" from Sativida OU (Estonia). The Issuer will license the trademark back to Sativida OU's subsidiary, VIDA BCN LABS S.L. in exchange for a royalty associated with the gross revenues generated by Sativida. The Issuer also acquired the right to acquire all of the outstanding share capital of Sativida at any time for €1.00. Sativida is a producer and online retailer of CBD and branded CBD products in various jurisdictions in Europe, including Spain, Portugal, Austria, Germany, France and the United Kingdom. The Issuer and Sativida will work together to build the Sativida brand in Europe and the Issuer expects to acquire Sativida in the future for €1.00.

On March 4, 2020, the Issuer engaged AGORA, an arms' length service provider, to deliver online advertising and marketing services for an initial twelve-month term. The fee for the services is C\$60,000, to be paid in five equal instalments over the term in common shares of the Issuer.

The Company also entered into a 12-month programmatic digital advertising campaign with Native Ads, Inc., an arms' length service provider, in March for a total cost of C\$80,000.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

On March 2, 2020, the Issuer agreed to terminate the letter of intent with Stillcanna Inc. dated February 25, 2020. The decision to end merger discussions was the result of current market conditions and negative investor sentiment.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

On March 26, 2020, the Issuer completed its acquisition of the Spanish trademark "Sativida" from Sativida OU (Estonia). The Issuer will license the trademark back to Sativida OU's subsidiary, VIDA BCN LABS S.L. in

exchange for a royalty associated with the gross revenues generated by Sativida. The Issuer also acquired the right to acquire all of the outstanding share capital of Sativida at any time for €1.00. Sativida is a producer and online retailer of CBD and branded CBD products in various jurisdictions in Europe, including Spain, Portugal, Austria, Germany, France and the United Kingdom.

8. Describe the acquisition of new customers or loss of customers.

The Issuer announced the launch of its new “Immune Support” product line under its First Class CBD brand on March 14, 2020. The Immune Support product line acquired over 5,500 new customers in the span of 12 days and continues to gain customers. Popularity of the Immune Support line is continuing to add to the Issuer’s customer base as the Immune Support line is gaining interest from customers that historically were hesitant to purchase CBD, but are now interested in the immune products and the potential anti-inflammatory benefits of CBD.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks. **None**
10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs. **None**
11. Report on any labour disputes and resolutions of those disputes if applicable. **None**
12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings. **None**
13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness. **None**
14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds⁽¹⁾
Common Shares	42,375	Consideration for the provision of advertising and marketing services	N/A

FORM 7 – MONTHLY PROGRESS REPORT

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾
Common Shares	5,496,221	Issued in connection with the Sativida transaction	Acquisition of Sativida trademark
Common Shares	549,622	10% finders' fee for the Sativida transaction	Finder's fee
Common Shares	109,924	Administration fee for assisting in the Sativida transaction	Administration fee

(1) State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons. **None**
16. Provide details of any changes in directors, officers or committee members. **None**
17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

In December 2019, the 2019 novel coronavirus ("COVID-19") surfaced in Wuhan, China. The World Health Organization declared a global emergency on January 30, 2020 with respect to the outbreak and then characterized it as a pandemic on March 11, 2020. The outbreak has spread throughout the United States, Europe and Canada, causing companies and various international jurisdictions to impose restrictions, such as quarantines, closures, cancellations and travel restrictions. While these effects are expected to be temporary, the duration of the business disruptions internationally and related financial impact cannot be reasonably estimated at this time. Such public health crises can result in volatility and disruptions in global supply chains, business operation and financial markets, as well as declining trade and market sentiment and reduced mobility of people, all of which could affect, interest rates, credit ratings, credit risk and inflation. The risks to the Issuer of such public health crises also include risks to employee health and safety and a slowdown or temporary suspension of operations in geographic locations impacted by an outbreak, labour shortages, travel and shipping disruption and shutdowns (including as a result of government regulation and prevention measures). At this point, COVID-19 has not negatively impacted the business of the Issuer and has instead led to an increase in online sales of new products. Despite the initial positive impact, the extent to which COVID-19 may impact the Issuer is uncertain and it is possible that COVID-19 may have a material adverse effect on the Issuer's business and financial condition.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated April 7, 2020.

Szascha Lim
Name of Director or Senior Officer

/s/Szascha Lim
Signature

Chief Financial Officer
Official Capacity

<i>Issuer Details</i>	For Month End	Date of Report
Name of Issuer		YY/MM/DD
Mota Ventures Corp.	March 2020	20/04/07
Issuer Address		
Suite 800 – 1199 W Hastings Street,		
City/Province/Postal Code	Issuer Fax No.	Issuer Telephone No.
Vancouver BC V6E 3T5	()	+1.604.423.4733
Contact Name	Contact Position	Contact Telephone No.
Joel Shacker	President & Director	+1.604.423.4733
Contact Email Address	Web Site Address	
IR@motaventuresco.com	www.motaventuresco.com	

FORM 7 – MONTHLY PROGRESS REPORT